Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AV-101 L-4-chlorokynurenine: Phase IIa started

    VistaGen Therapeutics Inc. (OTCQB:VSTA), South San Francisco, Calif. Product: AV-101 L-4-chlorokynurenine Business: Neurology Molecular target: NMDA receptor Description: NMDA receptor antagonist Indication: Treat major…

    Published on 11/16/2015
  • AVB-620: Phase I started

    Avelas Biosciences Inc., La Jolla, Calif. Product: AVB-620 Business: Diagnostic Molecular target: NA Description: IV fluorescent protease-activated peptide Indication: Diagnose lymph node metastases in breast cancer …

    Published on 11/16/2015
  • BI 695501: Completed Phase III enrollment

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: BI 695501 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Biosimilar of adalimumab, a human mAb against tumor necrosis factor…

    Published on 11/16/2015
  • BIOD-531: Phase IIa started

    Biodel Inc. (NASDAQ:BIOD), Danbury, Conn. Product: BIOD-531 Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Ultra-rapid-acting formulation of recombinant human insulin Indication: …

    Published on 11/16/2015
  • CYC065: Phase I started

    Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: CYC065 Business: Cancer Molecular target: Cyclin dependent kinase 2 (CDK2); Cyclin dependent kinase 9 (CDK9) Description: Second-generation …

    Published on 11/16/2015
  • Denintuzumab mafodotin: Phase II started

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Product: Denintuzumab mafodotin (SGN-CD19A) (formerly SGN-19A) Business: Cancer Molecular target: CD19 Description: Antibody-drug conjugate (ADC) composed of an anti-…

    Published on 11/16/2015
  • Firdapse amifampridine: Phase III started

    Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Coral Gables, Fla. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Product: Firdapse amifampridine Business: Autoimmune Molecular target: Potassium channel …

    Published on 11/16/2015
  • HuMax-IL8: Phase Ib started

    Cormorant Pharmaceuticals AB, Stockholm, Sweden Genmab A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark Product: HuMax-IL8 (formerly HuMax-Inflam/MDX-018) Business: Cancer Molecular target: Interleukin-8 (IL-8) (CXCL8) …

    Published on 11/16/2015
  • Irinotecan: Phase II started

    Baxalta Inc. (NYSE:BXLT), Deerfield, Ill. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. PharmaEngine Inc. (TPEx:4162), Taipei, Taiwan Product: Irinotecan (nal-IRI, Onivyde)) (MM-398) Business: Cancer …

    Published on 11/16/2015
  • ISIS 416858: Phase II started

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: ISIS 416858, ISIS-FXIRx, BAY 2306001 Business: Cardiovascular Molecular target: Factor XI Description: Factor…

    Published on 11/16/2015
  • ISIS-SMNRx: Extension study started

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-SMNRx Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2) Description: Antisense oligonucleotide that modulates …

    Published on 11/16/2015
  • LOXO-101: Phase II started

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Loxo Oncology Inc. (NASDAQ:LOXO), Stamford, Conn. Product: LOXO-101 Business: Cancer Molecular target: Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1); …

    Published on 11/16/2015
  • Nadolol: Completed Phase II enrollment

    Invion Ltd. (ASX:IVX), Brisbane, Australia Product: Nadolol (INV102) Business: Inflammation Molecular target: Adrenergic receptor beta (ADRB) Description: Adrenergic receptor beta (ADRB) antagonist Indication: Treat …

    Published on 11/16/2015
  • OMS ElectroImmunotherapy: Phase II started

    OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Product: OMS ElectroImmunotherapy, ImmunoPulse IL-12, DNA IL-12 Business: Cancer Molecular target: Interleukin-12 (IL-12) Description: DNA plasmid coding for IL-12 …

    Published on 11/16/2015
  • PNT2258: Phase II started

    Marina Biotech Inc. (Pink:MRNA), Bothell, Wash. ProNAi Therapeutics Inc. (NASDAQ:DNAI), Vancouver, B.C. Product: PNT2258 Business: Cancer Molecular target: B cell lymphoma 2 (BCL-2) (BCL2) Description: 24-base …

    Published on 11/16/2015
  • ProCervix: Phase I started

    Genticel S.A. (Euronext:GTCL), Labege, France Product: ProCervix (GTL001) Business: Cancer Molecular target: Human papillomavirus (HPV) antigens Description: Bivalent therapeutic cancer vaccine against HPV types 16 and …

    Published on 11/16/2015
  • RGSH4K: Phase I started

    Regeneus Ltd. (ASX:RGS), Pymble, Australia Product: RGSH4K Business: Cancer Molecular target: NA Description: Autologous tumor vaccine with the immunostimulant streptavidin Indication: Treat advanced solid tumors …

    Published on 11/16/2015
  • SST-6007: Phase II started

    Strategic Science and Technologies LLC, Cambridge, Mass. Product: SST-6007 Business: Genitourinary Molecular target: NA Description: Topical 5% sildenafil citrate cream Indication: Treat female sexual arousal disorder (…

    Published on 11/16/2015
  • Subcutaneous daratumumab: Phase Ib started

    Genmab A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Subcutaneous daratumumab (DARA-PH20) Business:…

    Published on 11/16/2015
  • Trabodenoson: Phase III start

    Inotek Pharmaceuticals Corp. (NASDAQ:ITEK), Lexington, Mass. Product: Trabodenoson (INO-8875) (formerly PJ-875) Business: Ophthalmic Molecular target: Adenosine A1 receptor (ADORA1) Description: Selective adenosine A1 …

    Published on 11/16/2015
  • Vepoloxamer: Phase II started

    Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Product: Vepoloxamer (MST-188) (formerly ANX-188) Business: Cardiovascular Molecular target: NA Description: Antithrombotic poloxamer that binds to hydrophobic …

    Published on 11/16/2015
  • VK5211: Phase II started

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Viking Therapeutics Inc. (NASDAQ:VKTX), San Diego, Calif. Product: VK5211 (formerly LGD-4033) Business: Musculoskeletal Molecular target: Androgen receptor …

    Published on 11/16/2015
  • VSN16R: Phase II started

    Canbex Therapeutics Ltd., London, U.K. Product: VSN16R Business: Musculoskeletal Molecular target: NA Description: Undisclosed antispastic oral small molecule Indication: Treat spasticity in multiple sclerosis (MS) …

    Published on 11/16/2015
  • ADXS-HER2: FDA hold

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Product: ADXS-HER2 (ADXS31-164) (formerly Lovaxin B, ADXS-cHER2) Business: Cancer Molecular target: Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Description…

    Published on 11/9/2015
  • AEB1102: Phase I started

    Aeglea BioTherapeutics Inc., Austin, Texas Product: AEB1102 Business: Cancer Molecular target: Arginase 1 (ARG1) Description: Pegylated human recombinant arginase 1 (ARG1) Indication: Treat advanced solid tumors …

    Published on 11/9/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993